As demonstrated by Compound 1 (C1) and OTSSP167, discoveries of novel Small Molecule Drugs (SMDs) that inhibit MELK can be potential therapies for cancers with high levels of MELK expression [36,39,40]. This evidence concerns the gene MELK and cancer.